(SOBI) Swedish Orphan Biovitrum - Ratings and Ratios
Haematology, Immunology, Specialty Care
SOBI EPS (Earnings per Share)
SOBI Revenue
Description: SOBI Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (publ) is a biopharma company specializing in medicines for haematology, immunology, and specialty care, with a global presence across Europe, North America, the Middle East, Asia, and Australia. The company operates through three main segments: Haematology, Immunology, and Specialty Care, offering a diverse portfolio of treatments for rare and serious diseases.
The companys product portfolio includes several key treatments, such as Alprolix and Elocta/Eloctate for haemophilia A and B, Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria, and Gamifant for hemophagocytic lymphohistiocytosis. Additionally, Sobi has a range of other medicines, including Doptelet, Kineret, Orfadin, Synagis, VONJO, and Zynlonta, targeting various conditions. The company also partners with other pharmaceutical companies, such as Sanofi and Apellis Pharmaceuticals, to develop and commercialize new treatments.
From a financial perspective, Sobi has a market capitalization of approximately 98.16 billion SEK, with a price-to-earnings ratio of 24.98 and a forward P/E of 25.45. The companys return on equity (RoE) stands at 9.08%, indicating a relatively stable financial performance. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue can be considered. For instance, Sobis revenue growth rate, gross margin percentage, and R&D expenditure as a percentage of revenue can provide insights into its operational efficiency and ability to invest in new product development.
Some additional KPIs that can be used to evaluate Sobis performance include its debt-to-equity ratio, operating cash flow margin, and the percentage of revenue generated from its key products. These metrics can help investors and analysts assess the companys financial health, operational efficiency, and dependence on specific products. By analyzing these KPIs in conjunction with the companys product portfolio and financial performance, a more comprehensive understanding of Sobis strengths and weaknesses can be gained.
SOBI Stock Overview
| Market Cap in USD | 9,968m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
SOBI Stock Ratings
| Growth Rating | 10.7% |
| Fundamental | 69.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -30.8% |
| Analyst Rating | - |
SOBI Dividends
Currently no dividends paidSOBI Growth Ratios
| Growth Correlation 3m | -23.2% |
| Growth Correlation 12m | -73.7% |
| Growth Correlation 5y | 88.1% |
| CAGR 5y | 10.96% |
| CAGR/Max DD 3y | 0.38 |
| CAGR/Mean DD 3y | 1.36 |
| Sharpe Ratio 12m | 0.46 |
| Alpha | -29.73 |
| Beta | 0.700 |
| Volatility | 29.75% |
| Current Volume | 278.9k |
| Average Volume 20d | 221.9k |
| Stop Loss | 264.2 (-3.2%) |
| Signal | -0.34 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (4.37b TTM) > 0 and > 6% of Revenue (6% = 1.62b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 0.10% (prev -18.33%; Δ 18.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 6.74b > Net Income 4.37b (YES >=105%, WARN >=100%) |
| Net Debt (11.76b) to EBITDA (9.75b) ratio: 1.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (347.2m) change vs 12m ago 0.70% (target <= -2.0% for YES) |
| Gross Margin 78.29% (prev 69.42%; Δ 8.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.01% (prev 32.40%; Δ 5.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.90 (EBITDA TTM 9.75b / Interest Expense TTM 1.03b) >= 6 (WARN >= 3) |
Altman Z'' 2.46
| (A) 0.00 = (Total Current Assets 12.30b - Total Current Liabilities 12.27b) / Total Assets 68.75b |
| (B) 0.34 = Retained Earnings (Balance) 23.43b / Total Assets 68.75b |
| (C) 0.09 = EBIT TTM 6.07b / Avg Total Assets 70.96b |
| (D) 0.73 = Book Value of Equity 21.73b / Total Liabilities 29.68b |
| Total Rating: 2.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.02
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 3.89% = 1.95 |
| 3. FCF Margin 15.08% = 3.77 |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda 1.29 = 1.33 |
| 6. ROIC - WACC 2.17% = 2.71 |
| 7. RoE 11.25% = 0.94 |
| 8. Rev. Trend 69.92% = 5.24 |
| 9. EPS Trend 12.73% = 0.64 |
What is the price of SOBI shares?
Over the past week, the price has changed by -1.09%, over one month by -0.29%, over three months by -5.41% and over the past year by -17.77%.
Is Swedish Orphan Biovitrum a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SOBI is around 259.04 SEK . This means that SOBI is currently overvalued and has a potential downside of -5.11%.
Is SOBI a buy, sell or hold?
What are the forecasts/targets for the SOBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 341.2 | 25% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 286.9 | 5.1% |
SOBI Fundamental Data Overview
Market Cap SEK = 92.99b (92.99b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 1.06b SEK (last quarter)
P/E Trailing = 21.3788
P/E Forward = 14.0647
P/S = 3.4478
P/B = 2.355
P/EG = 1.2918
Beta = 0.258
Revenue TTM = 26.97b SEK
EBIT TTM = 6.07b SEK
EBITDA TTM = 9.75b SEK
Long Term Debt = 8.53b SEK (from longTermDebt, last quarter)
Short Term Debt = 4.02b SEK (from shortTermDebt, last quarter)
Debt = 12.55b SEK (Calculated: Short Term 4.02b + Long Term 8.53b)
Net Debt = 11.76b SEK (from netDebt column, last quarter)
Enterprise Value = 104.48b SEK (92.99b + Debt 12.55b - CCE 1.06b)
Interest Coverage Ratio = 5.90 (Ebit TTM 6.07b / Interest Expense TTM 1.03b)
FCF Yield = 3.89% (FCF TTM 4.07b / Enterprise Value 104.48b)
FCF Margin = 15.08% (FCF TTM 4.07b / Revenue TTM 26.97b)
Net Margin = 16.21% (Net Income TTM 4.37b / Revenue TTM 26.97b)
Gross Margin = 78.29% ((Revenue TTM 26.97b - Cost of Revenue TTM 5.85b) / Revenue TTM)
Tobins Q-Ratio = 4.81 (Enterprise Value 104.48b / Book Value Of Equity 21.73b)
Interest Expense / Debt = 1.72% (Interest Expense 216.0m / Debt 12.55b)
Taxrate = 11.98% (528.0m / 4.41b)
NOPAT = 5.34b (EBIT 6.07b * (1 - 11.98%))
Current Ratio = 1.00 (Total Current Assets 12.30b / Total Current Liabilities 12.27b)
Debt / Equity = 0.32 (Debt 12.55b / last Quarter total Stockholder Equity 39.06b)
Debt / EBITDA = 1.29 (Net Debt 11.76b / EBITDA 9.75b)
Debt / FCF = 3.08 (Debt 12.55b / FCF TTM 4.07b)
Total Stockholder Equity = 38.87b (last 4 quarters mean)
RoA = 6.36% (Net Income 4.37b, Total Assets 68.75b )
RoE = 11.25% (Net Income TTM 4.37b / Total Stockholder Equity 38.87b)
RoCE = 12.80% (Ebit 6.07b / (Equity 38.87b + L.T.Debt 8.53b))
RoIC = 9.92% (NOPAT 5.34b / Invested Capital 53.84b)
WACC = 7.75% (E(92.99b)/V(105.54b) * Re(8.59%)) + (D(12.55b)/V(105.54b) * Rd(1.72%) * (1-Tc(0.12)))
Shares Correlation 3-Years: 96.97 | Cagr: 1.38%
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.31% ; FCFE base≈4.46b ; Y1≈3.39b ; Y5≈2.08b
Fair Price DCF = 103.5 (DCF Value 35.53b / Shares Outstanding 343.2m; 5y FCF grow -28.52% → 3.0% )
EPS Correlation: 12.73 | EPS CAGR: 17.63% | SUE: 1.02 | # QB: True
Revenue Correlation: 69.92 | Revenue CAGR: 17.12%